1. Emergence of Escherichia coli ST131 carrying carbapenemase genes, European Union/European Economic Area, August 2012 to May 2024.
- Author
-
Kohlenberg A, Svartström O, Apfalter P, Hartl R, Bogaerts P, Huang TD, Chudejova K, Malisova L, Eisfeld J, Sandfort M, Hammerum AM, Roer L, Räisänen K, Dortet L, Bonnin RA, Tóth Á, Tóth K, Clarke C, Cormican M, Griškevičius A, Khonyongwa K, Meo M, Niedre-Otomere B, Vangravs R, Hendrickx AP, Notermans DW, Samuelsen Ø, Caniça M, Manageiro V, Müller V, Mäkitalo B, Kramar U, Pirs M, Palm D, Monnet DL, Alm E, and Linkevicius M
- Subjects
- Humans, Europe epidemiology, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Microbial Sensitivity Tests, Multilocus Sequence Typing, Escherichia coli Proteins genetics, beta-Lactamases genetics, Escherichia coli genetics, Escherichia coli isolation & purification, Escherichia coli Infections epidemiology, Escherichia coli Infections microbiology, European Union, Bacterial Proteins genetics
- Abstract
Analysis of 594 isolates of Escherichia coli sequence type (ST)131 and its single locus variants carrying carbapenemase genes from 17 European Union/European Economic Area countries revealed acquisition of 18 carbapenemase variants, mainly in ST131 clades A and C. Most frequent were bla
OXA-244 (n = 230) and blaOXA-48 (n = 224), detected in 14 and 12 countries, respectively. Isolates carrying blaOXA-244 have increased rapidly since 2021. The increasing detection of carbapenemase genes in the E. coli high-risk lineage ST131 is a public health concern.- Published
- 2024
- Full Text
- View/download PDF